Processa Pharmaceuticals (PCSA): Oct 29 Form 8-K, NGC-Cap Phase 2 Oncology Readouts & Peer Brief vs. OCGN, NTLA, SGMO
PCSA
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) develops Next Generation Cancer (NGC) therapies designed to improve the safety and efficacy of proven, FDA-approved chemotherapies by altering their metabolism and biodistribution. On October 29, 2026, Processa filed a Current Report on Form 8-K (Items 8.01 and 9.01) updating investors on corporate and clinical developments.
At a $4.92 million Nasdaq market capitalization, PCSA trades at microcap valuation levels despite advancing NGC-Cap (next-generation capecitabine) in Phase 2 clinical testing for advanced or metastatic breast cancer in alignment with the FDA Project Optimus dose-optimization framework. Because NGC candidates build on established oncology mechanisms with known commercial markets, clinical risk profiles differ materially from novel, unvalidated targets.
Sector Peer Valuation & Catalyst Comparison
| Ticker | Company | Exchange | Market Cap | Primary Catalyst & Sector Focus |
|---|---|---|---|---|
| PCSA (Subject) | Processa Pharmaceuticals, Inc. | Nasdaq | $4.92M | Form 8-K (2026-10-29) · Clinical-Stage Oncology & Next-Generation Chemotherapy (NGC-Cap) |
| $OCGN | Ocugen, Inc. | Nasdaq | $260M | Clinical-stage oncology & blindness gene therapies |
| $NTLA | Intellia Therapeutics, Inc. | Nasdaq | $1.42B | Targeted clinical therapeutics & biomarker-driven trials |
| $SGMO | Sangamo Therapeutics, Inc. | Nasdaq | $115M | Clinical-stage biopharma & strategic pharma partnerships |
Verified SEC EDGAR Filing Metrics (PCSA · CIK 0001533743)
| Form | Filing Date | Disclosure Scope | EDGAR Source |
|---|---|---|---|
| 8-K | 2026-10-29 | SEC Form 8-K (Items: 8.01,9.01) | View EDGAR Filing → |
| DEF 14A | 2026-10-22 | SEC Form DEF 14A | View EDGAR Filing → |
| S-3 | 2026-10-09 | SEC Form S-3 | View EDGAR Filing → |
| 8-K/A | 2026-10-05 | SEC Form 8-K/A (Items: 8.01,9.01) | View EDGAR Filing → |
| 10-Q | 2026-08-14 | SEC Form 10-Q | View EDGAR Filing → |
What Active Traders & Microcap Desks Are Watching Next
Biotech-focused prop desks and life-sciences family offices in our vault are monitoring: (1) interim and final Phase 2 pharmacokinetic and safety data for NGC-Cap following the October 29 Form 8-K, (2) oncology partnering discussions, and (3) balance-sheet funding structure.
Primary sources (SEC EDGAR)
PCSA Form 8-K (2026-10-29): https://www.sec.gov/Archives/edgar/data/1533743/000114036126041116/ef20084530_8k.htmPCSA Form DEF 14A (2026-10-22): https://www.sec.gov/Archives/edgar/data/1533743/000114036126040520/ny20083166x3_def14a.htmPCSA Form S-3 (2026-10-09): https://www.sec.gov/Archives/edgar/data/1533743/000114036126039266/ny20083513x1_s3.htmPCSA Form 8-K/A (2026-10-05): https://www.sec.gov/Archives/edgar/data/1533743/000114036126038535/ef20083140_8ka.htmSee the dilution and promotion flags before you see the pitch.
Each week: the micro and small-caps now showing dilution or paid-promotion signals, with the SEC filing behind every flag. No recommendations, no price targets.